Septerna (SEPN) Expected to Post Quarterly Earnings on Monday

Posted by Brenda Bartman on Nov 2nd, 2026

Septerna (NASDAQ:SEPN – Get Free Report) will likely be issuing its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect Septerna to announce earnings of ($0.4150) per share and revenue of $20.78 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Septerna (NASDAQ:SEPN – Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.14. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. The company had revenue of $26.75 million for the quarter, compared to analyst estimates of $19.22 million. On average, analysts expect Septerna to post ($1.41) EPS for the current fiscal year and ($2.21) EPS for the next fiscal year.

Septerna Price Performance

Septerna stock opened at $44.00 on Monday. The stock has a market capitalization of $2.05 billion, a P/E ratio of -81.48 and a beta of 2.20. Septerna has a 12-month low of $17.55 and a 12-month high of $51.10. The firm’s 50-day moving average is $38.95 and its two-hundred day moving average is $32.10.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on SEPN shares. JPMorgan Chase & Co. raised their target price on shares of Septerna from $38.00 to $48.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 19th. HC Wainwright boosted their price target on Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Raymond James Financial reissued a “strong-buy” rating and set a $49.00 price target on shares of Septerna in a research note on Tuesday, August 11th. Guggenheim raised their price objective on Septerna from $45.00 to $51.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Finally, JonesTrading lifted their price objective on Septerna from $43.00 to $62.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $52.44.

Get Our Latest Report on SEPN

Insider Activity

In related news, SVP Daniel D. Long sold 3,333 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $37.83, for a total value of $126,087.39. Following the completion of the sale, the senior vice president directly owned 96,412 shares in the company, valued at approximately $3,647,265.96. The trade was a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Elizabeth Bhatt sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $44.00, for a total transaction of $1,100,000.00. Following the completion of the sale, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $7,665,196. The trade was a 12.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 32,333 shares of company stock worth $1,375,727. Insiders own 5.80% of the company’s stock.

Septerna Company Profile

(Get Free Report)

Septerna, Inc is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in a wide range of biological processes and represent an important source of potential drug targets.

The company’s research is powered by its Native State platform, which is designed to study GPCRs in their natural biological configuration and support the discovery of selective small-molecule compounds.